Regeneron Reports Positive Eylea Data From Late-Stage Study
Zacks Investment Research | Feb 09, 2020 09:18PM ET
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced positive two-year results from the phase III PANORAMA study on lead drug Eylea (aflibercept) Injection 2 mg at the Angiogenesis, Exudation, and Degeneration 2020 meeting in Miami, FL.
The study is evaluating Eylea in patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR).
Eylea is already approved to treat diabetic retinopathy (DR) in the United States.
Data showed that treatment with Eylea reduced the likelihood of vision-threatening events (proliferative diabetic retinopathy or anterior segment neovascularization) by at least 75% at two years. More than half (58%) of the patients in the untreated sham arm developed a vision-threatening complication (VTC) or center-involved diabetic macular edema (CI-DME) within two years of entering the trial, per a Kaplan-Meier analysis.
The two-year results also showed a greater benefit for Eylea patients treated at regular intervals compared to patients who received Eylea treatment less frequently.
These data reinforce that regular Eylea treatment can be highly effective at reducing the risk of new vision-threatening events among patients with moderately severe to severe NPDR.
Adverse events were consistent with the known profile of Eylea.
Regeneron also provided an update on the ongoing studies for high-dose (8 mg) aflibercept. A phase II study (CANDELA) evaluating high-dose aflibercept in wet age-related macular degeneration (wet AMD) is currently enrolling. Moreover, phase III studies planned for 2020 in wet AMD (PULSAR) and DME (PHOTON) will evaluate dosing intervals of 12 weeks or longer.
We note that Regeneron co-developed Eylea with the HealthCare unit of Bayer (DE:BAYGN) AG (OTC:BAYRY) . The company is solely responsible for sales of this eye drug and entitled to profits in the United States. However, it shares profits and losses from the ex-U.S. Eylea sales equally with Bayer, except in Japan where the company receives a royalty on net sales.
The PULSAR study is being sponsored by Bayer.
Eylea is currently approved for the treatment of patients with neovascular wet AMD, macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and DR.
Regeneron’s shares have lost 6.6% in the past year compared with the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.